Current Report Filing (8-k)
March 31 2017 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 29, 2017
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34637
|
|
20-1852016
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On March 29, 2017, Anthera Pharmaceuticals, Inc. (the
Company) issued a press release announcing results from the extension period of the Companys SOLUTION study of Sollpura. A copy of the press release is filed herewith as Exhibit 99.1.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press release dated March 29, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 30, 2017
|
|
|
|
Anthera Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Craig Thompson
|
|
|
|
|
|
|
Craig Thompson
|
|
|
|
|
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press release dated March 29, 2017
|
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024